Nicotinamide‑mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis

Wang,Tong; Cui,Huixia; Ma,Nan; Jiang,Youhong

doi:10.3892/ol.2013.1400

Nicotinamide‑mediated inhibition of SIRT1 deacetylase is associated with the viability of cancer cells exposed to antitumor agents and apoptosis

Authors:
- Tong Wang
- Huixia Cui
- Nan Ma
- Youhong Jiang
View Affiliations

Affiliations: Department of Medical Oncology, China Medical University, Shenyang, Liaoning 11001, P.R. China, College of Nursing, Liaoning Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: June 14, 2013 https://doi.org/10.3892/ol.2013.1400
Pages: 600-604

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Silent mating‑type information regulation 2, homolog 1 (SIRT1) represents an NAD+‑dependent deacetylase that regulates the processes of stress response and cell survival. However, the functions of SIRT1 in stress‑ and drug‑induced apoptosis remain elusive. The present study was designed to determine the effects of SIRT1 in tumor cells subjected to antitumor agent treatment and to identify the underlying mechanisms during the stress response. Several of the most commonly used antitumor medications [arsenic trioxide (As2O3), Taxol and doxorubicin (doxo)] were selected to treat MCF‑7 human breast cancer cells with or without nicotinamide (NAM) inhibition. 3‑(4,5‑Dimethyl‑2‑thiazolyl)‑2,5‑diphenyl‑2H‑tetrazolium bromide (MTT) was used to test cell viability. SIRT1 expression was tested by immunoblot analysis. The typical hallmarks of apoptosis (chromatin condensation, apoptotic bodies, sub G1 change and Annexin V+/PI‑ stained cells) were detected by Hoechst 33342 staining, flow cytometry and Annexin V+/PI‑ staining following NAM treatment. The cleavage of poly(ADP‑ribose) polymerase (PARP) and caspases 9, 6 and 7 was detected through immunoblot analysis. Augmented SIRT1 expression was observed only at low concentrations (>80% cell viability) and the inhibition of SIRT1 deacetylase by NAM decreased the viability of the cancer cells exposed to low concentrations of antitumor agents. NAM induced typical apoptosis in the MCF‑7 tumor cells, accompanied by the activation of the caspase cascade. SIRT1 promotes cellular survival at certain stress levels by its deacetylase function. The SIRT1 deacetylase inhibitor, NAM, triggers the activation of the caspase cascade and induces typical apoptosis in MCF‑7 cells.

View Figures

View References

1.	Imai S, Armstrong CM, Kaeberlein M and Guarente L: Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 403:795–800. 2000. View Article : Google Scholar : PubMed/NCBI
2.	Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007. View Article : Google Scholar : PubMed/NCBI
3.	Jang KY, Kim KS, Hwang SH, et al: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
4.	Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res. 15:4453–4459. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Stünkel W, Peh BK, Tan YC, et al: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J. 2:1360–1368. 2007.
6.	Chen J, Zhang B, Wong N, et al: Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res. 71:4138–4149. 2011. View Article : Google Scholar : PubMed/NCBI
7.	Lin SJ, Defossez PA and Guarente L: Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science. 289:2126–2128. 2000. View Article : Google Scholar : PubMed/NCBI
8.	Liu T, Liu PY and Marshall GM: The critical role of the class iii histone deacetylase SIRT1 in cancer. Cancer Res. 69:1702–1705. 2009. View Article : Google Scholar : PubMed/NCBI
9.	Wojcik M, Mac-Marcjanek K and Wozniak LA: Physiological and pathophysiological functions of SIRT1. Mini Rev Med Chem. 9:386–394. 2009. View Article : Google Scholar : PubMed/NCBI
10.	Milne JC, Lambert PD, Schenk S, et al: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 450:712–716. 2007. View Article : Google Scholar : PubMed/NCBI
11.	Rodgers JT, Lerin C, Haas W, et al: Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 434:113–118. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Yamakuchi M, Ferlito M and Lowenstein CJ: mir-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Luo J, Nikolaev AY, Imai S, et al: Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell. 107:137–148. 2001. View Article : Google Scholar : PubMed/NCBI
14.	Motta MC, Divecha N, Lemieux M, et al: Mammalian SIRT1 represses forkhead transcription factors. Cell. 116:551–563. 2004. View Article : Google Scholar : PubMed/NCBI
15.	McBurney MW, Yang X, Jardine K, et al: The absence of Sir2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol Cancer Res. 1:402–409. 2003.PubMed/NCBI
16.	Solomon JM, Pasupuleti R, Xu L, et al: Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol. 26:28–38. 2006. View Article : Google Scholar : PubMed/NCBI
17.	Sauve AA and Schramm VL: Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry. 42:9249–9256. 2003. View Article : Google Scholar : PubMed/NCBI
18.	Jackson MD, Schmidt MT, Oppenheimer NJ and Denu JM: Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem. 278:50985–50998. 2003. View Article : Google Scholar : PubMed/NCBI
19.	Borra MT, Langer MR, Slama JT and Denu JM: Substrate specificity and kinetic mechanism of the sir2 family of NAD+-dependent histone/protein deacetylases. Biochemistry. 43:9877–9887. 2004.
20.	Bitterman KJ, Anderson RM, Cohen HY, et al: Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J Biol Chem. 277:45099–45107. 2002. View Article : Google Scholar : PubMed/NCBI
21.	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar
22.	Lallemand-Breitenbach V, Zhu J, Chen Z and de Thé H: Curing APL through PML/RARA degradation by As2O3. Trends Mol Med. 18:36–42. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Chen G, Wang K, Yang BY, et al: Synergistic antitumor activity of oridonin and arsenic trioxide on hepatocellular carcinoma cells. Int J Oncol. 40:139–147. 2012.PubMed/NCBI
25.	Evens AM, Tallman MS and Gartenhaus RB: The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res. 28:891–900. 2004. View Article : Google Scholar : PubMed/NCBI
26.	Wang TH, Wang HS and Soong YK: Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer. 88:2619–2628. 2000. View Article : Google Scholar : PubMed/NCBI
27.	Jordan MA and Wilson L: Microtubules as a target for anticancer drugs. Nat Rev Cancer. 4:253–265. 2004. View Article : Google Scholar : PubMed/NCBI
28.	Arcamone F, Cassinelli G, Fantini G, et al: Adriamycin, 14-hydroxydaunomycin, a new antitumor antibiotic from S. Peucetius var. Caesius. Biotechnol Bioeng. 11:1101–1110. 1969. View Article : Google Scholar : PubMed/NCBI
29.	Gewirtz DA: A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 57:727–741. 1999. View Article : Google Scholar : PubMed/NCBI
30.	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Gewirtz DA: Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat. 62:223–235. 2000. View Article : Google Scholar : PubMed/NCBI
32.	Roninson IB, Broude EV and Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat. 4:303–313. 2001. View Article : Google Scholar : PubMed/NCBI
33.	Chu F, Chou PM, Zheng X, et al: Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res. 65:10183–10187. 2005. View Article : Google Scholar : PubMed/NCBI
34.	Robinson SP, Howe FA, Stubbs M and Griffiths JR: Effects of nicotinamide and carbogen on tumour oxygenation, blood flow, energetics and blood glucose levels. Br J Cancer. 82:2007–2014. 2000.PubMed/NCBI
35.	Hirst DG, Joiner B and Hirst VK: Blood flow modification by nicotinamide and metoclopramide in mouse tumours growing in different sites. Br J Cancer. 67:1–6. 1993. View Article : Google Scholar : PubMed/NCBI
36.	Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65:10457–10463. 2005. View Article : Google Scholar : PubMed/NCBI
37.	Zhao X, Allison D, Condon B, et al: The 2.5 Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition. J Med Chem. 56:963–969. 2013.